{"id":"W4383314786","doi":"10.1016/s0140-6736(23)00774-2","title":"First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study","year":2023,"lang":"en","type":"article","venue":"The Lancet","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":158,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Atezolizumab; Medicine; Internal medicine; Regimen; Population; Chemotherapy regimen; Oncology; Chemotherapy; Vinorelbine; Clinical endpoint; Performance status; Lung cancer; Gemcitabine; Phases of clinical research; Cancer; Surgery; Clinical trial; Pembrolizumab; Immunotherapy; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00172426,0.001542209,0.004031894,0.0003881107,0.0003048501,0.001308498,0.0009410935,0.002092502,0.004010484],"category_scores_gemma":[0.001666779,0.0007278957,0.003239373,0.0004584184,0.001279739,0.0014296,0.0004818116,0.003783775,0.0006621864],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009272896,"about_ca_system_score_gemma":0.0008857226,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009355351,"about_ca_topic_score_gemma":0.002158483,"domain_scores_codex":[0.9993762,0.0003300198,0.00003838092,0.000112402,0.00004038468,0.0001026121],"domain_scores_gemma":[0.9988899,0.0003837448,0.0002598116,0.00008150026,0.00005440262,0.0003306406],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9838412,0.002933899,0.0008727936,0.0005621479,0.001159945,0.00002670207,0.00004104848,0.0002490361,0.001236022,0.00004858935,0.0004175034,0.008610997],"study_design_scores_gemma":[0.9215202,0.07371721,0.002856814,0.00004130279,0.000846218,0.00003291489,0.0000305429,0.0002923043,0.0001919412,0.0001060557,0.0003464099,0.00001805895],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9892344,0.006548705,0.0003665366,0.0007009124,0.0006304808,0.0009359065,0.0006212628,0.00005372775,0.0009081513],"genre_scores_gemma":[0.9924425,0.002606326,0.000688437,0.001060358,0.0003801483,0.0008069118,0.0006392488,0.0000164185,0.001359717],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004031894,"threshold_uncertainty_score":0.01341635,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05724716795188822,"score_gpt":0.3473963572473626,"score_spread":0.2901491892954744,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}